ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcomes of Primary Simultaneous Pancreas-Kidney Transplants by Induction Agent in the United States

A. Cerise1, T. Shaker1, K. Ramanathan1, S. Jackson2, R. Kandaswamy1, S. Riad3

1Surgery, University of Minnesota, Minneapolis, MN, 2Analytics, MHealth-Fairview, Minneapolis, MN, 3Medicine, University of Minnesota, Minneapolis, MN

Meeting: 2022 American Transplant Congress

Abstract number: 432

Keywords: Immunosuppression, Induction therapy, Kidney/pancreas transplantation, Outcome

Topic: Clinical Science » Pancreas » 65 - Pancreas and Islet: All Topics

Session Information

Session Name: Pancreas and Islet: All Topics

Session Type: Rapid Fire Oral Abstract

Date: Tuesday, June 7, 2022

Session Time: 3:30pm-5:00pm

 Presentation Time: 4:20pm-4:30pm

Location: Hynes Room 210

*Purpose: Induction immunosuppression choice for simultaneous pancreas-kidney (SPK) transplants varies widely in the United States. We examined the association between induction agents and outcomes of SPK recipients discharged on tacrolimus and mycophenolate.

*Methods: We used the Scientific Registry of Transplant Recipients to examine all primary SPK transplants between 2000 and 2020, excluding crossmatch positive recipients and those with other induction regimens. We grouped recipients according to induction regimen used into three groups: anti-thymocyte globulin (n=5678), alemtuzumab (n=1199), and IL-2 RA (n=1593). Delayed graft function, acute kidney, and pancreas rejection rates were compared by type of induction. We analyzed the ten-year recipient and composite (kidney and pancreas) grafts survival using Kaplan-Meier survival function. Cox proportion hazard models were utilized to examine the association between induction type and the ten-year recipient and grafts survival. Models were adjusted for recipient age, sex, ethnicity, HLA-MM, diabetes type, dialysis dependency, cold ischemia time, local vs imported organs, PRA, steroid maintenance, and PDRI.

*Results: Delayed graft function rate was observed in less than 6.5% of the recipients and did not differ between groups P=0.68. One-year kidney rejection rates were observed in 8.9% of the anti-thymocyte group, 9.5% of the IL-2RA group and 13% in the alemtuzumab group (p<0.001). Similarly, one-year pancreas rejection rates were observed in 9.5% of the anti-thymocyte group, 12.4% of the IL-2RA group and 14.1% in the alemtuzumab group (p<0.001). In the univariable analysis, induction type was not associated with recipient (log-rank p=0.11) or grafts survival (log-rank p=0.36) (Figure 1). In the multivariable model for the composite grafts survival, alemtuzumab use was associated with 22% increased kidney or pancreas graft loss compared to anti-thymocyte globulin (LLCI, aHR, ULCI) (1.05, 1.22, 1.42), while IL-2RA use was not a predictor of grafts survival. Induction type didn’t influence recipient survival in the adjusted model.

*Conclusions: Anti-thymocyte globulin use was associated with the lowest kidney and pancreas rejection rates. Compared to anti-thymocyte globulin, alemtuzumab but not IL-2RA was associated with worse long-term death-censored SPK grafts outcome. Our analysis supports the US national popularity of anti-thymocyte globulin induction in primary SPK recipients.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Cerise A, Shaker T, Ramanathan K, Jackson S, Kandaswamy R, Riad S. Outcomes of Primary Simultaneous Pancreas-Kidney Transplants by Induction Agent in the United States [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-primary-simultaneous-pancreas-kidney-transplants-by-induction-agent-in-the-united-states/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences